Consulting Fees Honoraria

Related by string. * consulted . consults . consulting . Consults . consult . CONSULTING : Iron Consulting delivers . Neither Iron Consulting . Iron Consulting receives . consulting firm . Always consult your . Deloitte Consulting / feeing . FEE' . FEE . FEES . fees : Prescription Drug User Fee . finder fee . Finder Fee . finder fees . retainer fee / honoraria : Sociedad Honoraria Hispanica . Honoraria * *

Related by context. Frequent words. (Click for all words.) 66 Presents Positive 65 Inc Therapeutic Competitors 64 FDA Clears 63 Initiates Phase II 63 Receives Orphan Drug Designation 63 Announces FDA Clearance 62 Completes Enrollment 62 Develop Novel 62 FDA Accepts 60 Inflammatory Diseases 60 Drug Candidate 60 Beats Views 59 Announces Presentation 59 Small Molecule 59 RNAi Therapeutics 59 Sees Positive 58 Earnings Decline 58 Preclinical Data 58 MLNM 58 QLTI 58 OSI Pharma 58 Anti Infectives 57 Adverse Reactions 57 Beats Forecasts 57 Patent Covering 57 Exploit collaboration 56 CureDM 56 Takeda Kyowa Hakko Kirin 56 Tops Estimates 56 Corp. Nasdaq GENZ 56 ICOS Corporation 56 Japanese Stocks Climb 56 Lower Than Expected 56 Idera Pharmaceuticals 56 Idenix Pharmaceuticals 56 Antipsychotic 56 Progenics Pharmaceuticals 56 DepoMed 55 Raises Forecast 55 Preclinical Development 55 PHARMACEUTICALS 55 Beats Estimates 55 CYTR 55 Teva Pharma 55 Onyx Pharma 55 Below Estimates 55 Cardiometabolic 55 Benign Prostatic Hyperplasia 55 Edges Higher 54 Drug Interactions 54 Beats Expectations 54 Beat Expectations 54 Sees Higher 54 Bayhill Therapeutics 54 AVEO Pharmaceuticals 54 Investors Await 54 Atopic Dermatitis 54 Biopharm 53 Announce Collaboration 53 Profits Surge 53 Cancer Res 53 Profits Rise 53 Biogen IDEC 53 Beat Estimates 53 Biomaterial 53 Bioavailability 53 Small Molecules 53 #:#-# [006] 52 Cancer Vaccines 52 Recombinant Human 52 Falls Sharply 52 Allergan AGN 52 Stocks Little Changed 52 Higher Than Expected 52 Weaker Yen 52 Up Sharply 52 Encysive Pharmaceuticals 52 Stocks Recover 52 Copegus R 52 Detailed Product 51 Inflation Worries 51 Slower Growth 51 Inch Higher 51 Licensing Agreements 51 Modest Gains 51 Edges Up 51 Hepatitis C Virus 51 Pharmas 51 Sharply Higher 51 NV Organon 51 Dyslipidemia 51 Drop Sharply 51 gets USFDA nod 51 Hepatocellular Carcinoma 51 Biogenerics 51 www.gsk.com 51 Percent Jump 51 Stocks Dip 51 Stronger Dollar 51 Better Than Expected 50 Erlotinib

Back to home page